Navigation Links
Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
Date:3/19/2008

ical antifungal steroid combination, and Novacort(R) (2% hydrocortisone acetate and 1% pramoxine HCl), a prescription topical steroid and anesthetic. CollaGenex recently completed a Phase II clinical trial to evaluate COL-118, a topical compound based on the SansRosa(R) technology, for the treatment of redness associated with rosacea and other skin disorders. CollaGenex recently acquired the rights to develop and commercialize becocalcidiol, a patented Vitamin D analogue that is currently in Phase II clinical trials for the topical treatment of mild to moderate psoriasis.

For more information on CollaGenex please visit CollaGenex's Web site at http://www.collagenex.com, which does not form part of this press release.

Important Information About the Tender Offer

Galderma Laboratories, Inc. and its wholly owned subsidiary, Galderma Acquisition Inc., have filed a Tender Offer Statement on Schedule TO containing an offer to purchase, forms of letters of transmittal and other documents relating to the tender offer, and CollaGenex Pharmaceuticals, Inc. has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. These documents contain important information about the tender offer that should be read carefully before any decision is made with respect to the tender offer.

Shareholders of CollaGenex can obtain a free copy of these documents and other documents filed by CollaGenex or Galderma Laboratories, Inc. with the U.S. Securities and Exchange Commission at their website, http://www.sec.gov, or from the Information Agent, Innisfree M&A Incorporated, through the numbers listed at the end of this press release.

Forward Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects may constitute forwar
'/>"/>

SOURCE Galderma Pharma S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
2. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
3. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
4. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
5. The Pennsylvania Breast Cancer Coalition Announces Event at the University of Pennsylvania Hospital to Celebrate the 2008 Income Tax Check-Off Campaign
6. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
7. PRA International Announces New Office Opening in Mumbai
8. Cardiums InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue Systems
9. Varian Announces Global Clinical Council to Develop RapidArc(TM) Cancer Treatments
10. Forest Laboratories Announces Resignation of Ivan Gergel, MD
11. National Parkinson Foundation Announces Its New President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Recently, Fadhits.com, the distinguished wedding dress ... kids prom dresses . To bring more benefits to worldwide ... launched a special offer for these brand new items. Clients ... The company’s sales manager says gladly, “We are happy to ... is to acknowledge all new and old customers and strengthen ...
(Date:7/11/2014)... Hills, CA (PRWEB) July 11, 2014 Bedros ... marketing expert; a title he’s earned by founding the fast-selling ... professionals on marketing their businesses. He works with successful boot ... blog post on the traits of the most successful ... earners share three important qualities. , “I’ve worked with and ...
(Date:7/11/2014)... CO (PRWEB) July 11, 2014 H.E.A.R ... A new organization launches this week to provide comprehensive ... Reaching almost half a million Coloradoans with hearing ... to provide all encompassing information of the local and ... the deaf and hearing impaired. , H.E.A.R. Me Out ...
(Date:7/11/2014)... 11, 2014 (HealthDay News) -- Polio is history in ... like Afghanistan, Nigeria and Pakistan. Giving vaccinated children an ... immunity and help eradicate the highly infectious disease, a ... highly effective, immunity wanes as early as a year ... infected and contribute to the spread of the disease, ...
(Date:7/11/2014)... 11, 2014 Recent research findings regarding Fourth ... atmosphere, and how water affects human bodies. That was the ... during an interview on the Sharon Kleyne Hour Power of ... , Gerald Pollack, PhD, is a Professor of Bioengineering at ... Phase of Water (Ebner & Sons, 2013). , ...
Breaking Medicine News(10 mins):Health News:Promotion for Kids Prom Dresses Now Provided at Fadhits.com 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 2Health News:Fitness Boot Camp Marketing Expert Bedros Keuilian Shares the Top Three Traits of Successful Boot Camp Owners 3Health News:H.E.A.R Me Out Listens to Needs of Hearing Impaired 2Health News:H.E.A.R Me Out Listens to Needs of Hearing Impaired 3Health News:Researchers Assess New Way to Boost Polio Immunity 2Health News:Recent Fourth Phase Water Discoveries Alter Basic Understanding of Life, Claims Researcher on Sharon Kleyne Hour 2Health News:Recent Fourth Phase Water Discoveries Alter Basic Understanding of Life, Claims Researcher on Sharon Kleyne Hour 3
... (HealthDay News) -- Many people with peanut or tree nut allergies, ... types of nuts just by looking at them, a new study ... were asked to identify each of 19 nuts in a display ... and some were chopped, sliced or diced, similar to how they ...
... News) -- People who have experienced recent changes in ... hospital emergency departments, a new study finds. ... of access to care. People who have difficulty obtaining ... care, said Dr. Adit Ginde, of the University of ...
... By Serena Gordon HealthDay Reporter , FRIDAY, ... many people, those with allergies may not be as thrilled ... those beautiful blooms is plenty of pollen that has hay-fever ... And, in some areas, not only is the season ...
... School of Medicine indicates that CT scans are more effective ... cancers in their most treatable stages. The data, published online ... lung cancers found through annual CT screening are similar to ... growth rates and cell-type distribution. In fact, the report showed ...
... the world will benefit from better training and testing of ... for Advanced Medical Learning and Simulation (CAMLS) in downtown Tampa. ... in the world, CAMLS is expected to draw 30,000 health ... advanced surgical skills, in interdisciplinary teams, and to have their ...
... , FRIDAY, March 30 (HealthDay News) -- There appears ... as obstructive sleep apnea and major depression, a new study ... in the back of the throat blocks the upper airway ... sleep symptoms such as snorting, gasping and snoring. In ...
Cached Medicine News:Health News:Most People Can't Tell a Tree Nut From a Peanut 2Health News:Changes in Insurance Make ER Visits More Likely: Study 2Health News:Warm Weather Triggers Early Allergy Season 2Health News:Warm Weather Triggers Early Allergy Season 3Health News:Lung cancers detected by CT screening grow as fast as those found with traditional methods 2Health News:Lung cancers detected by CT screening grow as fast as those found with traditional methods 3Health News:USF Health's center for training and evaluating health professionals sets standards for quality care 2Health News:USF Health's center for training and evaluating health professionals sets standards for quality care 3Health News:USF Health's center for training and evaluating health professionals sets standards for quality care 4
(Date:7/11/2014)... 11, 2014 Research and Markets ( ... "Immunoprotein Diagnostic Testing Market - Forecasts to ... of 6% and is expected to be valued ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... has been segmented according to immunoprotein types which ...
(Date:7/11/2014)... SAN DIEGO , July 11, 2014 ... Therapies Corp. ("Biotie") to end the option held by ... to commence further development of NRL-1 (intranasal diazepam) for ... seizures. Over the past year, Biotie has ... Neurelis in preparation for the pivotal clinical work required ...
(Date:7/10/2014)... 2014  The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... test a unique model developed at UH to enhance ... comorbidities, or demonstrated need for high health care utilization.  ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: